Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

eyepoint - EYPT

EYPT

Close Chg Chg %
11.70 0.12 1.03%

Closed Market

11.82

+0.12 (1.03%)

Volume: 736.32K

Last Updated:

May 19, 2026, 4:00 PM EDT

Trade Now

Company Overview: eyepoint - EYPT

EYPT Key Data

Open

$11.69

 Day Range

11.40 - 12.02

52 Week Range

5.46 - 19.01

 Market Cap

$980.94M

Shares Outstanding

83.84M

 Public Float

78.13M

Beta

1.77

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.50

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

841.59K

  

EYPT Performance

1 Week
 
 -4.29%
 
1 Month
 
 -20.83%
 
3 Months
 
 -22.90%
 
1 Year
 
 108.10%
 
5 Years
 
 26.42%
 

EYPT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About eyepoint - EYPT

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EYPT At a Glance

EyePoint, Inc.
480 Pleasant Street
Watertown, Massachusetts 02472
Phone 1-617-926-5000 Revenue 31.37M
Industry Pharmaceuticals: Major Net Income -231,962,000.00
Sector Health Technology Employees 214
Fiscal Year-end 12 / 2026
View SEC Filings

EYPT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 42.66
Price to Book Ratio 4.943
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.375
Enterprise Value to Sales 33.63
Total Debt to Enterprise Value 0.022

EYPT Efficiency

Revenue/Employee 146,593.458
Income Per Employee -1,083,934.579
Receivables Turnover 48.189
Total Asset Turnover 0.08

EYPT Liquidity

Current Ratio 8.877
Quick Ratio 8.828
Cash Ratio 8.267

EYPT Profitability

Gross Margin 86.054
Operating Margin -775.984
Pretax Margin -738.526
Net Margin -739.415
Return on Assets -59.29
Return on Equity -72.193
Return on Total Capital -70.525
Return on Invested Capital -67.702

EYPT Capital Structure

Total Debt to Total Equity 7.446
Total Debt to Total Capital 6.93
Total Debt to Total Assets 6.262
Long-Term Debt to Equity 6.786
Long-Term Debt to Total Capital 6.315
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Eyepoint - EYPT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
41.40M 46.02M 43.27M 31.37M
Sales Growth
+12.09% +11.14% -5.97% -27.50%
Cost of Goods Sold (COGS) incl D&A
10.38M 4.63M 3.71M 4.38M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.45M 464.00K 1.54M 2.31M
Depreciation
396.00K 464.00K 1.54M 2.31M
Amortization of Intangibles
- - - 2.05M
-
COGS Growth
-2.45% -55.36% -19.86% +17.86%
Gross Income
31.03M 41.39M 39.56M 27.00M
Gross Income Growth
+17.97% +33.38% -4.41% -31.76%
Gross Profit Margin
+74.94% +89.93% +91.42% +86.05%
2022 2023 2024 2025 5-year trend
SG&A Expense
109.97M 115.05M 185.41M 270.43M
Research & Development
49.64M 64.36M 132.93M 221.04M
Other SG&A
60.32M 50.69M 52.49M 49.39M
SGA Growth
+34.80% +4.62% +61.16% +45.85%
Other Operating Expense
- - - -
-
Unusual Expense
- - 22.26M 2.75M
-
EBIT after Unusual Expense
(101.20M) (76.41M) (145.85M) (243.43M)
Non Operating Income/Expense
2.13M 6.95M 15.09M 11.78M
Non-Operating Interest Income
2.13M 6.95M 15.09M 11.78M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.19M 1.25M 14.00K 33.00K
Interest Expense Growth
-42.00% -60.90% -98.88% +135.71%
Gross Interest Expense
3.19M 1.25M 14.00K 33.00K
Interest Capitalized
- - - -
-
Pretax Income
(102.25M) (70.71M) (130.78M) (231.68M)
Pretax Income Growth
-75.04% +30.85% -84.95% -77.15%
Pretax Margin
-246.97% -153.66% -302.22% -738.53%
Income Tax
- 83.00K 90.00K 279.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(102.25M) (70.80M) (130.87M) (231.96M)
Minority Interest Expense
- - - -
-
Net Income
(102.25M) (70.80M) (130.87M) (231.96M)
Net Income Growth
-75.04% +30.77% -84.86% -77.25%
Net Margin Growth
-246.97% -153.84% -302.43% -739.42%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(102.25M) (70.80M) (130.87M) (231.96M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(102.25M) (70.80M) (130.87M) (231.96M)
EPS (Basic)
-2.7402 -1.8197 -2.3246 -3.1667
EPS (Basic) Growth
-34.90% +33.59% -27.75% -36.23%
Basic Shares Outstanding
37.32M 38.90M 56.30M 73.25M
EPS (Diluted)
-2.7402 -1.8197 -2.3246 -3.1667
EPS (Diluted) Growth
-34.90% +33.59% -27.75% -36.23%
Diluted Shares Outstanding
37.32M 38.90M 56.30M 73.25M
EBITDA
(76.49M) (73.20M) (144.31M) (241.13M)
EBITDA Growth
-45.69% +4.31% -97.16% -67.08%
EBITDA Margin
-184.75% -159.06% -333.50% -768.62%

Snapshot

Average Recommendation BUY Average Target Price 37.00
Number of Ratings 12 Current Quarters Estimate -0.919
FY Report Date 06 / 2026 Current Year's Estimate -3.497
Last Quarter’s Earnings -0.99 Median PE on CY Estimate N/A
Year Ago Earnings -3.17 Next Fiscal Year Estimate -2.826
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 12 12
Mean Estimate -0.92 -0.81 -3.50 -2.83
High Estimates -0.77 -0.46 -2.69 -0.98
Low Estimate -1.20 -0.99 -4.09 -4.60
Coefficient of Variance -12.68 -22.55 -14.15 -39.85

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 11
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Eyepoint - EYPT

Date Name Shares Transaction Value
Apr 21, 2026 Ramiro Ribeiro Chief Medical Officer 2,437 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.26 per share 20,129.62
Apr 21, 2026 Ramiro Ribeiro Chief Medical Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15 per share 0.00
Apr 21, 2026 Ramiro Ribeiro Chief Medical Officer 80,438 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Nancy Sue Lurker Director 12,667 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 George O. Elston Chief Financial Officer 15,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 George O. Elston Chief Financial Officer 39,333 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 George O. Elston Chief Financial Officer 63,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 George O. Elston Chief Financial Officer 81,054 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.43 per share 1,412,771.22
Jan 8, 2026 George O. Elston Chief Financial Officer 85,457 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 George O. Elston Chief Financial Officer 70,457 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.48 per share 1,231,588.36
Jan 8, 2026 George O. Elston Chief Financial Officer 76,781 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 74,965 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Reginald J. Sanders Director 40,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Nancy Sue Lurker Director 219,213 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 30,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 130,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 331,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 165,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Jay S. Duker President and CEO; Director 67,013 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.43 per share 1,168,036.59
Jan 8, 2026 Jay S. Duker President and CEO; Director 81,518 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Eyepoint in the News